Early-stage therapeutics Seranova Bio is an early-stage biotech focused on groundbreaking therapeutics using the REAP platform, presenting a need for strategic partnerships, CRO services, and academic collaborations to accelerate discovery and de-risk programs.

Unique platform The REAP rapid extracellular antigen profiling technology represents a differentiator that could be attractive to pharma and biotech partners seeking novel immune interaction insights, co-development opportunities, or licensing discussions.

Investors backing With funding from notable investors (Foresite Capital Management and The Column Group), Seranova has credibility and capital runway which can support outreach for strategic collaborations, milestone-driven deals, and multi-stage partnerships.

Regional focus Located in South San Francisco, Seranova sits in a dense biotech ecosystem with proximity to potential collaborators, contract research organizations, and talent pools to accelerate partnerships and joint development efforts.

Growth readiness Revenue range and modest headcount indicate an opportunity for scalable collaboration models, such as research collaborations, sponsored programs, or early-access licensing, aligned with the company’s growth trajectory and funding.